Vanguard Group Inc. Has $83.10 Million Holdings in Indivior PLC $INDV

Vanguard Group Inc. decreased its stake in shares of Indivior PLC (NASDAQ:INDV) by 38.6% in the 3rd quarter, according to its most recent Form 13F filing with the Securities & Exchange Commission. The institutional investor owned 3,465,813 shares of the company’s stock after selling 2,181,496 shares during the period. Vanguard Group Inc. owned approximately 2.51% of Indivior worth $83,104,000 at the end of the most recent quarter.

Other hedge funds and other institutional investors have also made changes to their positions in the company. State of New Jersey Common Pension Fund D boosted its stake in Indivior by 32.2% in the 3rd quarter. State of New Jersey Common Pension Fund D now owns 23,472 shares of the company’s stock worth $566,000 after purchasing an additional 5,714 shares during the period. Aberdeen Group plc bought a new stake in shares of Indivior in the third quarter valued at about $3,875,000. LSV Asset Management acquired a new position in shares of Indivior during the third quarter worth about $489,000. Plato Investment Management Ltd acquired a new position in shares of Indivior during the third quarter worth about $52,000. Finally, Envestnet Asset Management Inc. bought a new position in shares of Indivior during the third quarter worth about $325,000. 60.33% of the stock is currently owned by institutional investors and hedge funds.

Insider Buying and Selling at Indivior

In related news, Director Barbara Ryan acquired 775 shares of the company’s stock in a transaction dated Monday, January 5th. The shares were bought at an average cost of $35.39 per share, with a total value of $27,427.25. Following the completion of the transaction, the director directly owned 1,963 shares of the company’s stock, valued at $69,470.57. This trade represents a 65.24% increase in their ownership of the stock. The acquisition was disclosed in a filing with the SEC, which is accessible through the SEC website. Also, Director Keith Humphreys purchased 775 shares of the firm’s stock in a transaction that occurred on Monday, January 5th. The stock was bought at an average price of $35.39 per share, for a total transaction of $27,427.25. Following the purchase, the director owned 5,802 shares in the company, valued at $205,332.78. The trade was a 15.42% increase in their position. The SEC filing for this purchase provides additional information. Over the last ninety days, insiders have acquired 4,871 shares of company stock worth $172,385.

Indivior Trading Down 0.3%

Shares of INDV opened at $32.05 on Friday. The company’s fifty day simple moving average is $34.19 and its 200 day simple moving average is $30.23. Indivior PLC has a 1-year low of $8.64 and a 1-year high of $38.00. The company has a market cap of $4.01 billion, a price-to-earnings ratio of 19.54 and a beta of 0.83.

Indivior (NASDAQ:INDV) last released its quarterly earnings data on Thursday, February 26th. The company reported $0.82 earnings per share (EPS) for the quarter, beating the consensus estimate of $0.65 by $0.17. Indivior had a negative return on equity of 148.76% and a net margin of 16.85%.The firm had revenue of $358.00 million for the quarter, compared to analyst estimates of $305.62 million. As a group, research analysts forecast that Indivior PLC will post 1.22 earnings per share for the current year.

Wall Street Analysts Forecast Growth

Several research firms have commented on INDV. Northland Securities set a $50.00 target price on Indivior in a research note on Tuesday, January 20th. HC Wainwright lifted their price objective on shares of Indivior from $35.00 to $48.00 and gave the company a “buy” rating in a report on Monday, January 12th. Zacks Research lowered shares of Indivior from a “strong-buy” rating to a “hold” rating in a research report on Tuesday, January 13th. Weiss Ratings upgraded shares of Indivior from a “hold (c)” rating to a “buy (b-)” rating in a report on Monday. Finally, Morgan Stanley reiterated an “overweight” rating and issued a $36.00 price target on shares of Indivior in a research note on Wednesday, December 3rd. Six equities research analysts have rated the stock with a Buy rating and one has assigned a Hold rating to the stock. According to data from MarketBeat.com, the company presently has an average rating of “Moderate Buy” and a consensus target price of $39.33.

Indivior Profile

Indivior plc is a specialty pharmaceutical company dedicated to developing and delivering treatments for addiction and related mental health disorders. The company’s portfolio centers on therapies designed to support individuals dealing with opioid dependence, alcohol use disorder and other behavioral health challenges. Its lead products include Suboxone® (buprenorphine and naloxone) sublingual film and Sublocade® (extended-release buprenorphine) injection, both of which are approved in multiple markets to aid in opioid use disorder management.

Indivior was established in 2014 through a demerger from the pharmaceuticals division of Reckitt Benckiser Group plc, inheriting decades of research and commercial expertise in addiction medicine.